Truist Securities initiates coverage on Dianthus Therapeutics stock with Buy rating

Investing.com - Truist Securities initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and a price target of $56.00 on Tuesday. The stock, currently trading at $34.42 with a market capitalization of $1.33 billion, has shown remarkable momentum with an 84% gain over the past six months. According to InvestingPro data, analysts’ price targets range from $40 to $100, suggesting significant upside potential.

The research firm cited Dianthus’ differentiated approach to targeting the autoantibody mediated complement cascade through C1s inhibition as a key factor in its positive outlook.

Truist Securities believes this approach may offer similar efficacy as available complement inhibitors but with a cleaner safety profile, according to its research note.

The firm pointed to recent Phase 2 proof-of-concept results with claseprubart in generalized myasthenia gravis (gMG) as supportive of this thesis.

Truist Securities also noted that the gMG data are relatively de-risking for the ongoing Phase 3 chronic inflammatory demyelinating polyneuropathy (CIDP) trial, for which the firm sees significant upside potential upon positive data expected in the second half of 2026.

In other recent news, Dianthus Therapeutics has successfully closed a public offering, raising approximately $288 million in gross proceeds. This offering involved the sale of 7,627,879 shares of common stock at $33.00 per share, including the full exercise of underwriters’ options for additional shares. Furthermore, Jefferies has raised its price target for Dianthus Therapeutics to $66.00, citing positive data from the company’s Phase II trial for generalized myasthenia gravis (gMG) as a significant factor. H.C. Wainwright has maintained its Buy rating and a $40.00 price target for the company, following positive results from its Phase 2 MaGic study evaluating the drug claseprubart for gMG. Additionally, Clear Street has initiated coverage on Dianthus Therapeutics with a Buy rating and a $100.00 price target, highlighting the potential of the drug claseprubart in treating autoimmune conditions. The recent developments indicate a strong interest from analysts and investors in the company’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.